SI1549333T1 - Analogi kompstatina z izboljĺ ano aktivnostjo - Google Patents

Analogi kompstatina z izboljĺ ano aktivnostjo

Info

Publication number
SI1549333T1
SI1549333T1 SI200332088T SI200332088T SI1549333T1 SI 1549333 T1 SI1549333 T1 SI 1549333T1 SI 200332088 T SI200332088 T SI 200332088T SI 200332088 T SI200332088 T SI 200332088T SI 1549333 T1 SI1549333 T1 SI 1549333T1
Authority
SI
Slovenia
Prior art keywords
improved activity
compounds
peptides
disclosed
compstatin analogues
Prior art date
Application number
SI200332088T
Other languages
English (en)
Inventor
John D Lambris
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of SI1549333T1 publication Critical patent/SI1549333T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI200332088T 2002-09-20 2003-09-22 Analogi kompstatina z izboljĺ ano aktivnostjo SI1549333T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41222002P 2002-09-20 2002-09-20
PCT/US2003/029653 WO2004026328A1 (en) 2002-09-20 2003-09-22 Compstatin analogs with improved activity
EP03759343A EP1549333B1 (en) 2002-09-20 2003-09-22 Compstatin analogues with improved activity

Publications (1)

Publication Number Publication Date
SI1549333T1 true SI1549333T1 (sl) 2012-02-29

Family

ID=32030834

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200332088T SI1549333T1 (sl) 2002-09-20 2003-09-22 Analogi kompstatina z izboljĺ ano aktivnostjo

Country Status (13)

Country Link
US (4) US7989589B2 (sl)
EP (3) EP1549333B1 (sl)
JP (3) JP4614222B2 (sl)
AT (1) ATE525082T1 (sl)
AU (1) AU2003275075A1 (sl)
CA (2) CA2502690C (sl)
CY (1) CY1112198T1 (sl)
DK (1) DK1549333T3 (sl)
ES (1) ES2373649T3 (sl)
HK (2) HK1156860A1 (sl)
PT (1) PT1549333E (sl)
SI (1) SI1549333T1 (sl)
WO (1) WO2004026328A1 (sl)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1549333T1 (sl) * 2002-09-20 2012-02-29 Univ Pennsylvania Analogi kompstatina z izboljĺ ano aktivnostjo
US8048437B2 (en) 2004-04-21 2011-11-01 Richard Nagler Medical device with surface coating comprising bioactive compound
WO2007044668A2 (en) * 2005-10-08 2007-04-19 Potentia Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
CA2971349C (en) * 2005-11-28 2020-09-08 The Trustees Of The University Of Pennsylvania Potent compstatin analogs
AU2013200981B2 (en) * 2005-11-28 2016-01-14 The Trustees Of The University Of Pennsylvania Potent compstatin analogs
ES2545775T3 (es) 2007-02-05 2015-09-15 Apellis Pharmaceuticals, Inc. Análogos de compstatina para uso en el tratamiento de afecciones inflamatorias del sistema respiratorio
US8442776B2 (en) 2007-06-08 2013-05-14 The Trustees Of The University Of Pennsylvania Structure of compstatin-C3 complex and use for rational drug design
US8563259B2 (en) 2007-06-29 2013-10-22 The Trustees Of The University Of Pennsylvania Complement-mediated thrombophilic assay
US20110092446A1 (en) * 2007-07-20 2011-04-21 Cedric Francois Compositions and methods for treatment of trauma
RU2505311C2 (ru) * 2007-10-02 2014-01-27 Потентия Фармасьютикалз, Инк. Пролонгированная доставка аналогов компстатина из гелей
WO2009105217A2 (en) 2008-02-19 2009-08-27 The Trustees Of The University Of Pennsylvania Complement inhibitors as therapeutic agents for treatment of cancer
EP2278987A4 (en) * 2008-03-28 2012-08-22 Apellis Ag MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
CA2734866A1 (en) 2008-08-20 2010-02-25 The Trustees Of The University Of Pennsylvania Complement inhibitors for treatment of injury from intracerebral hemorrhage
WO2010039690A1 (en) 2008-09-30 2010-04-08 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
ES2655389T3 (es) * 2009-05-01 2018-02-19 The Trustees Of The University Of Pennsylvania Compstatina modificada con esqueleto peptídico y modificaciones c-terminales
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
WO2011053774A1 (en) 2009-10-30 2011-05-05 Alcon Research, Ltd. Single nucleotide polymorphisms and genes associated with age-related macular degeneration
WO2011106635A1 (en) 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
CA2813049A1 (en) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
WO2012095519A1 (en) 2011-01-13 2012-07-19 Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie Potent inhibitors of complement activation
US20140219999A1 (en) 2011-04-01 2014-08-07 The Trustees Of The University Of Pennsylvania Treatment of colon cancer using complement inhibitors
RU2653439C9 (ru) 2011-05-11 2018-10-16 Апеллис Фармасьютикалс, Инк. Клеточно-реактивные аналоги компстатина, аналоги компстатина длительного действия или аналоги компстатина нацеленного действия и их применение
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
AU2012272706B2 (en) 2011-06-22 2017-07-06 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
HUE047375T2 (hu) 2011-09-07 2020-04-28 Univ Pennsylvania Javított farmakokinetikai tulajdonságokkal rendelkezõ compstatin analógok
DK2920201T3 (da) * 2012-11-15 2020-04-14 Apellis Pharmaceuticals Inc Langtidsvirkende compstatin-analoger og relaterede sammensætninger og fremgangsmåder
WO2014078734A2 (en) * 2012-11-15 2014-05-22 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
CA3107872A1 (en) 2013-12-12 2015-06-18 Alnylam Pharmaceuticals, Inc. Complement component irna compositions and methods of use thereof
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
US10213476B2 (en) 2014-03-17 2019-02-26 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved potency and pharmacokinetic properties
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017062879A2 (en) 2015-10-07 2017-04-13 Apellis Pharmaceuticals, Inc. Dosing regimens
MX2019010381A (es) 2017-03-01 2020-01-21 Achillion Pharmaceuticals Inc Compuestos farmaceuticos de arilo, heteroarilo y heterociclicos para el tratamiento de trastornos medicos.
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CN116059313A (zh) 2017-04-07 2023-05-05 阿佩利斯制药有限公司 给药方案以及相关组合物和方法
SG11202002940QA (en) 2017-11-01 2020-04-29 Alnylam Pharmaceuticals Inc Complement component c3 irna compositions and methods of use thereof
MX2020008902A (es) 2018-02-27 2020-12-03 Zp Spv 3 K/S Analogos de compstatina y sus usos medicos.
JP7423070B2 (ja) 2018-04-06 2024-01-29 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 増加した溶解度および改善された薬物動態特性を有するコンプスタチンアナログ
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
AU2019336238A1 (en) 2018-09-06 2021-04-08 Achillion Pharmaceuticals, Inc. Morphic forms of Complement factor D inhibitors
CA3114039A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
BR112022003760A2 (pt) 2019-08-27 2022-05-31 Zp Spv 3 K/S Análogos de compstatina e seus usos médicos
AU2020369515A1 (en) 2019-10-22 2022-04-21 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof
EP4114947A1 (en) 2020-03-05 2023-01-11 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
JP2023523790A (ja) 2020-04-30 2023-06-07 アルナイラム ファーマシューティカルズ, インコーポレイテッド 補体因子B(CFB)iRNA組成物およびその使用方法
JP2023526051A (ja) 2020-05-12 2023-06-20 アレクシオン ファーマシューティカルズ, インコーポレイテッド 発作性夜間ヘモグロビン尿症の処置のための補体d因子阻害剤の単独又は抗c5抗体との組み合わせでの使用
JP2023538807A (ja) 2020-07-16 2023-09-12 セッドぺー エスぺーヴェー 3 カー/エス 補体因子c3の阻害剤及びそれらの医学的使用
EP4274896A1 (en) 2021-01-05 2023-11-15 Alnylam Pharmaceuticals, Inc. Complement component 9 (c9) irna compositions and methods of use thereof
WO2023044370A2 (en) 2021-09-17 2023-03-23 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing complement component 3 (c3)
TW202333749A (zh) 2021-10-29 2023-09-01 美商艾拉倫製藥股份有限公司 補體因子b(cfb)irna組成物及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2295746A1 (fr) 1974-12-23 1976-07-23 Francaise Coop Pharma Nouveaux derives du tryptophane a activite nerveuse centrale renforcee
IT1179866B (it) 1984-12-12 1987-09-16 Rotta Research Lab Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono
US4576750A (en) 1985-04-22 1986-03-18 Merck & Co., Inc. Tryptophan derivative
US4807097A (en) * 1986-05-14 1989-02-21 Gammache Richard J Miniature flashlight
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US5167960A (en) 1988-08-03 1992-12-01 New England Deaconess Hospital Corporation Hirudin-coated biocompatible substance
WO1991016345A1 (en) 1990-04-23 1991-10-31 Rijksuniversiteit Te Utrecht Cyclic peptides and their use
EP0750458B1 (en) 1994-03-03 2003-08-27 Alexion Pharmaceuticals, Inc. Terminal complement inhibitor fusion genes and proteins
US5776970A (en) 1994-04-28 1998-07-07 Yeda Research And Development Co. Ltd. Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases
EP0894002A4 (en) 1996-03-13 2001-11-14 Univ Pennsylvania NEW PEPTIDES INHIBITING SUPPLEMENT ACTIVATION
US6221621B1 (en) * 1997-03-06 2001-04-24 Bard Diagnostic Sciences, Inc. Methods of screening for colorectal cancers in which a complement Factor I or related protein is associated
US6169057B1 (en) 1997-09-04 2001-01-02 The Regents Of The University Of California Use of tryptophan and analogs as plant growth regulators
AU4648197A (en) * 1997-09-17 1999-04-05 Burnham Institute, The Peptides and peptidomimetics for inhibiting complement activation
AU3485999A (en) 1998-04-10 1999-11-01 Mayo Foundation For Medical Education And Research Neo-tryptophan
SI1549333T1 (sl) * 2002-09-20 2012-02-29 Univ Pennsylvania Analogi kompstatina z izboljĺ ano aktivnostjo
CA2971349C (en) * 2005-11-28 2020-09-08 The Trustees Of The University Of Pennsylvania Potent compstatin analogs

Also Published As

Publication number Publication date
CA2833202C (en) 2017-08-01
AU2003275075A1 (en) 2004-04-08
WO2004026328A1 (en) 2004-04-01
ATE525082T1 (de) 2011-10-15
ES2373649T3 (es) 2012-02-07
EP2311479B1 (en) 2014-07-23
JP5860573B2 (ja) 2016-02-16
JP2013138673A (ja) 2013-07-18
HK1156862A1 (en) 2012-06-22
EP2311480A1 (en) 2011-04-20
US20180118785A1 (en) 2018-05-03
US20100222550A1 (en) 2010-09-02
US20170190741A9 (en) 2017-07-06
EP2311480B1 (en) 2013-06-26
DK1549333T3 (da) 2012-01-16
US7989589B2 (en) 2011-08-02
US20110275150A1 (en) 2011-11-10
EP2311479A1 (en) 2011-04-20
CA2502690A1 (en) 2004-04-01
HK1156860A1 (en) 2012-06-22
US8883413B2 (en) 2014-11-11
JP4614222B2 (ja) 2011-01-19
CA2502690C (en) 2014-01-28
JP2006505254A (ja) 2006-02-16
CY1112198T1 (el) 2015-12-09
JP2010280688A (ja) 2010-12-16
EP1549333A1 (en) 2005-07-06
US20150158913A1 (en) 2015-06-11
EP1549333B1 (en) 2011-09-21
CA2833202A1 (en) 2004-04-01
EP1549333A4 (en) 2008-05-28
PT1549333E (pt) 2012-01-03

Similar Documents

Publication Publication Date Title
SI1549333T1 (sl) Analogi kompstatina z izboljĺ ano aktivnostjo
WO2007062249A3 (en) Potent compstatin analogs
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
IL172403A0 (en) D-amino acid peptides
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
EP1071443A4 (en) ISOLATED PEPTIDES CORRESPOND THE NY-ESO-1 AMINO ACID SEQUENCES AND BIND TO MHC CLASS I AND MHC CLASS II MOLECULES AND THEIR USE
AUPP472398A0 (en) Protease susceptibility II
ATE362487T1 (de) N-substituierte l-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
AU2003223923A1 (en) Peptide nucleic acid conjugates with transporter peptides
WO2002046407A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
ATE375360T1 (de) Peptide mit inhibierender aktivität zur produktion von stickstoffmonoxid
AU2003217174A8 (en) Novel variants of rankl protein
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
AU2003295435A1 (en) Biological carriers for the delivery of proteins or peptides
WO2001081412A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding the same, and uses thereof
WO2001081413A3 (en) Isolated human transporter proteins, nucleic acids and uses thereof
WO2002022678A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2001000655A3 (en) Therapeutic peptides derived from subsequences of bpi
WO2002020757A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002046217A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002033086A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002024748A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002077261A3 (en) Human potassium channel
WO2002048364A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof